Docetaxel

Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.

7-Epi-10-oxo-docetaxel (Docetaxel Impurity 2) is a docetaxel impurity identified by HPLC.

Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis.

10-Oxo Docetaxel is a Docetaxel intermediate having remarkable antitumor properties.

7-Epi-10-oxo-docetaxel (7-Epitaxotere) is a impurity of docetaxel.

Docetaxal (10-Acetyl docetaxel) is an analogue of Docetaxel, which is a microtubule inhibitor. Docetaxal can be used in cancer research.

Docetaxel (Standard) is a reference standard for research and analysis in studies involving Docetaxel. Docetaxel (RP-56976) is a semi-synthetic analog of paclitaxel, a microtubule depolymerization inhibitor (IC50=0.2 μM). Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.

Sudocetaxel is a compound that serves as a microtubule depolymerization inhibitor, specifically designed for the pH-sensitive delivery of docetaxel.

Docetaxel-d9 is a deuterated compound of Docetaxel. Docetaxel has a CAS number of 114977-28-5. Docetaxel is a microtubule inhibitor that inhibits microtubule disassembly (IC50: 0.2 μM).

Sudocetaxel zendusortide functions as an antineoplastic [1].

Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.

DUPA(OtBu)-OH is a precursor of DUPA, which is used as a targeting moiety to actively deliver Docetaxel (DTX) for treating Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer, with PSMA showing high affinity for DUPA (Ki = 8 nM).

Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel or docetaxel [2].

Larotaxel (XRP9881) is a taxane analogue with anticancer activity that promotes tubulin assembly and stabilizes microtubules, inducing apoptosis. It crosses the blood-brain barrier and has a higher affinity for Docetaxel than P-glycoprotein 1, making it useful for studying breast and bladder cancer.

PNR-3-80 is a selective inhibitor of apoptotic endonuclease G (EndoG), with an IC50 of 0.67 μM, showing greater inhibition than against DNase I. It exhibits no inhibitory activity against DNase II, RNase A, proteases, lactate dehydrogenase, and superoxide dismutase 1. PNR-3-80 effectively protects human prostate cancer cells from cell death induced by Cisplatin and Docetaxel and inhibits DNA damage and autophagy (autophagy) prompted by Etoposide. This compound is applicable in studies of cellular damage.

1-Deoxyceramide (m18:1/20:0) is a type of ceramide. Its levels increase in the dorsal root ganglia of mice treated with Docetaxel.

Gαi2-IN-1 (Compound 14) is an inhibitor of Gαi2 that significantly suppresses cancer cell migration induced by chemotherapeutic agents such as Vorinostat and Docetaxel. It is applicable in research involving various cancers, including prostate, breast, and ovarian cancers.

Tunlametinib is a highly selective, orally bioavailable small molecule inhibitor of MEK1 and MEK2 kinases with a reported IC50 value of 1.9 nM for MEK1. Tunlametinib exerts its antitumor effects by blocking the oncogenic RAS-RAF-MEK-ERK signaling pathway, thereby inducing tumor cell cycle arrest and promoting apoptosis, Tunlametinib demonstrates strong inhibitory activity against various RAS/RAF-mutant cancer cells such as those harboring BRAF V600E or KRAS G12C mutations, shows synergistic effects in combination with BRAF/KRASG12C/SHP2 inhibitors and Docetaxel, and is used in targeted therapy for RAS/RAF-driven cancers including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC).

ALDH3A1-IN-1 (Compound 18) is a potent ALDH3A1 inhibitor with an IC 50 of 1.61 μM. It is more effective than DEAB against patient-derived primary prostate tumor epithelial cells, both as a single agent and in combination with docetaxel [1].

Gemcitabine-ibandronate (GEM–IB), a conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB), exhibits efficacy both as a monotherapy and synergistically with Docetaxel (DTX), resulting in diminished tumor burden, maintained bone structure, and enhanced survival in a murine osteosarcoma (OS) model [1].

CYP1B1-IN-7 is a selective and potent CYP1B1 inhibitor showing cytotoxic effects in docetaxel-resistant CYP1B1 overexpressing MCF-7 cell lines, and can be used in synergistic treatment of cancer with anticancer compounds.

Bisdemethoxycurcumin is a natural curcumin derivative that activates the AMPKα pathway to attenuate LPS-induced acute lung injury; reversibly inhibits tyrosinase and possesses anti-browning ability; enhances the antiprostate cancer efficacy of docetaxel (DTX); targets cellular pathways involved in oxidative stress and apoptosis; and is an anticancer agent.

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.

DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90.